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Abstract
Background: We report on a female patient who underwent primary radical resection for a stage 2B Her-2-positive
Barrett’s-type esophageal adenocarcinoma (EAC). Despite Her-2 targeted therapy, her disease recurred and required
repeated metastectomies.
Case presentation: Digital cell sorting and targeted sequencing of cancer sub-clones from EAC and metastases
revealed a completely mutated TP53, whereas the sorted stromal cells were wild-type. Her-2 amplification was
significantly lower in the metastases when the patient became therapy-resistant.
Conclusions: The mechanism of therapy resistance illustrated by this case could only be detected through
accurate analysis of tumor sub-populations.
Investigating tumor sub-populations of recurrent disease is important for adjusting therapy in recurrent EAC.
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Background
The incidence of esophageal adenocarcinomas (EACs) is
increasing, and the survival rate is low, despite the adop-
tion of aggressive therapeutic protocols [1]. EACs are
characterized by a high mutational frequency and fre-
quent somatic structural rearrangements (copy number
variations, CNVs) [2, 3]. However, because of admixture
of stromal cells the exact status of somatic cancer alter-
ations is difficult to be determined. Next Generation
Sequencing (NGS) technologies hold the potential to
reveal the molecular underpinnings of tumor biology
with the accuracy required for clinical implementation.
However, when the input DNA is a mixture of normal
and tumor there is an inherent trade-off between sensi-
tivity and specificity, further complicated by the fact
that the tumor DNA derive from subpopulations with
different genetic characteristics. This can dilute the
signal from the variant alleles/copy number alterations
to values close to the background noise or below the
detection limit. We exploited an automatic sorting system
enabling isolation of pure tumor cells for unambiguous
genetic analysis with targeted NGS assays, to investigate at
the molecular level a primary EAC and two metachronous
metastases [4].
Case presentation
We studied the case of a woman who underwent primary
radical resection of an EAC, adjuvant chemo-radiotherapy,
targeted chemotherapy and two-stage resection of chest
metastases (Additional file 1). We combined next gener-
ation sequencing (NGS) with a high-throughput cell
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sorting technique to separate stromal from cancer cells
and identified diverse somatic mutations underlying the
primary EAC and metastases.
Whole Exome Sequencing (WES) of the primary
EAC and the two metachronous chest metastases re-
vealed a somatic heterozygous TP53 missense mutation
(chr17:g.7577094G >A,NP_000537.3: p.Arg282Trp, rs289
34574, Fig. 1a), which was absent in the patient’s blood
DNA (Fig. 1b). Cancer cells showed homogenous clusters
in the primary tumor and metastases (Fig. 1ci). Intense
immune-histochemical staining for p53, as detected in the
EAC tumor area compared to no staining in the normal
counterparts (Fig. 1cii), was consistent for a TP53 mis-
sense mutations [5]. Using a selective sorting technology
to separate cancer from stromal cell populations, we iso-
lated 9 cancer and 9 stromal populations (Additional file 1:
Table S1). Targeted NGS performed using the OncoSeek
panel revealed that TP53 was completely mutated in the
EAC and metastatic clusters, while wild-type in the stromal
cells (Fig. 2a – row 13). The purity of the sorted samples
also detected several loss-of-heterozygosity (LOH) events
involving the cancer-related genes on chromosome 4
PDGFRA, KIT (Fig. 2a – row 1–6), CDK6 and MET on
chromosome 7 in the primary EAC and metastases
(Fig. 2a – row 7–12). Despite the lower purity of WES
data, the B-allele frequency (BAF) profiles were consistent
with the identified LOH events (Fig. 2b). Analysis of
Copy Number Alteration (CNA), evaluated using the
WES data on the whole primary tumor and metastases,
showed a clear Her-2 amplification, shared by primary
tumor and both metastasis (Additional file 1: Table S2)
and an additional gain of the chromosomal region
6q21–22.33 (18 Mb), that in the second chest metastasis
generated a focal amplification (39 copies) spanning
RNF146 and ECHDC1 genes (Additional file 2: Figure
S1A-C, Additional file 1: Table S2). ECHDC1 copy gains




Fig. 1 TP53 p.Arg282Trp mutation. a Representation of the TP53 mutation (Integrative Genomic Viewer, IGV) and (b) Sanger sequencing of EAC,
metastasis and blood. c (i) Histological appearance of the primary EAC; (ii) TP53-immunoreactivity (low power magnification)






Fig. 2 (See legend on next page.)
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SNP-based phylogenetic analysis with SNPhylo [6],
using the WES data, revealed that the two chest metas-
tases diverged in two branches derived from the primary
lesion. Each metastasis presented the same phylogenetic
distance from primary EAC, given by the sum of each
branch length between the two samples (Additional file 2:
Figure S1D).
The Her-2 rs1565923A > G intronic variant showed a
~ 100% frequency in the tumor populations and un-
sorted samples, suggesting a high level of copy-gains
(Fig. 2a – row 14). In concordance, CNV analysis of the
sorted cell populations revealed also high level of Her-2
amplification in the tumor subpopulations, confirmed by
the WES data on unsorted material (Fig. 2b).
All sorted stromal cell populations did not carry this
amplification (Fig. 2c, d). Interestingly, in the sorted cell
populations the Her2 fold-change decreased from ≅70-fold
in the primary tumor to approximately ≅45-fold in the two
recurrent chest metastases that subsequently developed.
The fold-changes were not significantly different be-
tween the metastases (one-way ANOVA, p < 0.01 M2/PT,
p < 0.05 M1/PT, Fig. 2c).
Using routine diagnostic techniques, no differences were
observed in Her-2-immunostaining between the primary le-
sion and chest metastases (Fig. 2ei-vi). In situ hybridization
(ISH) using a silver staining (SISH) method [7], showed
clusters of Her-2 amplification in the primary and the meta-
static tumor sites, with a Her-2/CEP17 ratio > 2 and Her-2
copy number > 6 (clusters). Differences between the sam-
ples could not be appreciated with SISH, since all samples
presented amplification clusters (Fig. 2fi-iii).
Discussion
TP53 mutations are considered early genetic events in
Barrett’s esophagus associated with an increased risk of
progression to cancer [2, 3, 8]. In general, it is difficult
to assess whether a somatic mutation involves only one
copy of a gene or both alleles in whole tumor tissue
samples, due to stromal cell contamination. According
to our data, the TP53 mutant allele was completely
mutated in the primary cancer, indicating that the TP53
locus might have been involved in an early LOH
event, which can explain the homozygous state of the
p.Arg282Trp mutation. This mutation is frequently
reported in several cancers (COSM10704, COSMIC;
http://cancer.sanger.ac.uk/) and, as constitutive muta-
tion, causes Li Fraumeni syndrome (ClinVar id12347;
https://www.ncbi.nlm.nih.gov/clinvar/), an inherited can-
cer disease, characterized by autosomal dominant inherit-
ance due to heterozygous mutations in TP53, with early
onset and multiple tumors within an individual, including
soft tissue sarcomas and osteosarcomas, breast cancer,
brain tumors, leukemia and adrenocortical carcinoma
(OMIM #151623). In our case, the variant was somatic, as
indicated by its absence from peripheral blood-derived
DNA (Fig. 1b).
The complete loss of TP53 wild-type protein in the
studied tumor provides a significant impact on prognosis
and therapeutic options, since the p.Arg282Trp muta-
tion abolishes specific DNA binding, allowing evasion
from apoptosis and accelerating tumor progression [8].
The pharmacological reactivation of mutant TP53 emerged
as a promising strategy using molecules that restore its
wild-type activity, such as APR-246/PRIMA-1Met, which
is already under clinical trials for different cancers, includ-
ing EAC [9, 10]. This molecule restores TP53 activity in
presence of missense mutations and regulates several
TP53-related pathways [9]. Therefore, precise identification
of the TP53 mutational status in EAC could be instrumen-
tal for selecting more efficient therapies. In the present
case, the TP53 mutation was shared by the EAC primary
tumor and metastases (suggestive of an early origin) and
we propose that restoring TP53 wild-type activity could be
effective for metastases. From a technical perspective, the
high-throughput sorting of the tumor cells led to the iden-
tification of somatic alterations without a “diluting” effect
due to the presence of normal stromal cells. In addition,
the capability of sorting pure stromal cells provides a con-
venient internal control [4]. Analyzing only the tumor but
not matched normal tissue can yield many false-positive
(See figure on previous page.)
Fig. 2 Variant identification in sorted cell populations (stromal and tumor) from primary EAC and chest metastases. a Relevant variants in the
sorted pure populations of tumor (red), stromal (blue) cells and unsorted fractions (violet). Numeric values represent the alternative allele
frequency. Table cells with gray background highlight positions with very low coverage. b BAF plot obtained using WES data of the primary EAC
and a control female individual (WES performed on genomic DNA derived from peripheral blood). In the tumor track, the green lines highlight
the positions of genes with putative LOH events detected using the OncoSeek panel. While the control profile shows a flat signal centered
around 50%, as expected for a normal germline DNA, EAC tumor profile highlights several consistent regions with abnormal allele frequency,
describing putative copy-number altered regions. Given the high variability of allele frequency, due to the relative low coverage in WES, a local
smoothing on 20 Mb-long regions, represented by red dots, was calculated specifically to mitigate the frequency variability and to give a sharper
idea of copy-number alterations at genome-level. c Her-2 fold-change in all sorted pure populations (stromal and tumor). Histogram of CNV
differences in the primary EAC and metastases. * = p < 0.05,** = p < 0.001, NS = not significant (ANOVA test). d Her-2 Copy-number analysis using
EAC WES data on unsorted material. e (i) Histological appearance and Her-2-immunoreactivity in the primary EAC (i-ii), M1 (iii-iv) and M2 (v-vi)
metastases. f Her2 cluster amplification detected by Ventana’s Her2 SISH test in primary EAC (i), M1 (ii) and M2 (iii) metastases. Clusters are
represented by black areas in the nuclei (normal signal: black dots)
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alterations that are not specific to the patient’s tumor.
When matched normal tissue is unavailable, as may be the
case for archival samples, this method can provide a valu-
able surrogate.
Standard tests measure Her-2 CNV to guide the use of
the anti-Her-2 drug trastuzumab in patients with meta-
static disease secondary to gastric/gastroesophageal can-
cer, since ~ 24% of gastroesophageal adenocarcinomas
overexpress Her-2 [11]. However, trastuzumab-responsive
patients may develop resistance, due to Her-2-dependent
mechanisms such as the overexpression of proteins that
mask the Her-2 receptor (e.g., MUC1), Her-2 alternative
splicing, or Her-2-independent mechanisms [12]. In the
present case, compared to the primary tumor, the Her-2
copy numbers detected by the selective cell sorting
coupled to NGS were significantly lower in the metastases
developed after trastuzumab therapy (Fig. 2a). This de-
crease was not detected by SISH, which showed clusters
of the Her-2 amplified region in the primary and meta-
static tissues. Notably, the areas of metastatic tissues sam-
pled for the CNV and ISH tests were morphologically
homogeneous. The lower copy number in the metastases
indicates a selection of sub-clones more resistant to treat-
ment, although the histological appearance of the cells in
the tumor areas was homogeneous. CNV analysis with
WES data also showed a gain in RNF146-ECHDC1 copy
number, in the second metastasis. RNF146 encodes for a
E3 ubiquitin ligase ring finger protein 146, a critical
regulator of Wnt/β-catenin signaling, whose overexpres-
sion, for example reported in non-small cell lung cancer,
enhanced cell growth, invasion, and survival [13, 14].
ECHDC1 encodes for a proofreading enzyme involved in
lipid metabolism, with an increased expression observed in
resistant bladder cancer cells [15]. We hypothesize that the
acquired RNF146-ECHDC1 copy gain in the cells giving
raise to the second metastasis, coupled to the loss of cells
with HER2 amplification, might contributes to resistance
and progression in metastatic EAC cancer. Sub-clone
molecular heterogeneity is also revealed by the detection of
somatic events in other cancer genes at different degrees.
Conclusions
Digital cell sorting and omics-technologies in a Barrett’-
s-type EAC and two metachronous metastases revealed:
(1) the true tumor cell mutational status of the somatic
mutations and CNVs; (2) a progressive reduction of Her-2
copy-gains in the two recurrent metastases compared to
the primary tumor, not detectable by ISH.
We demonstrated that a genomic dissection of EAC
and recurrent metastases could identify the tumor cell
mutational status, as in this case for a TP53 mutation
and Her2 copy-gains. Our pilot study took advantage of
an available target panel for cancer-related genes, for the
study of specific mutations in digitally-sorted cell
populations from formalin-embedded tissue biopsies. Not-
ably, a WES approach in unsorted material could identify
additional CNVs in the different samples, but not the true
tumor cell mutational status. It is therefore of key import-
ance to apply whole exome/genome approaches to sorted
cell populations from formalin-embedded tissue samples,
in order to gain a global view of all the tumor alterations,
as it is already applied for circulating tumor cells or fresh
tumor tissues [16].
The incorporation of genomic differences in cancer
cell sub-populations with currently available clinical vari-
ables can further stratify patients, in order to select the ones
with highest risk of malignant progression for targeted
therapies.
Additional files
Additional file 1: Supplementary methods and metarials. (DOCX 79 kb)
Additional file 2: Figure S1. Plots of Copy Number Analysis and
phylogenetic tree using WES data. A 18 Mb region on chromosome 6
(q21-22.33) is indicated (red box), where CNV analysis identified a copy
gain in PT (A) and M1 (B), as reported in Additional file 1: Table S2. (C) In
the second chest metastasis (M2) a focal amplification was detected in
the 6q22.33 region, spanning RNF146 and ECHDC1 genes (black arrowhead).
(D) SNPhylo analysis results, showing the genetic distance between the
three tumor samples. Numbers indicate the branch length from central
node. The distance between two tumors is equal to the sum of their branch
length. Analysis was performed according to [6]. (PDF 137 kb)
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